Codexis reports FY2022 revenue $138.6M (+32% YoY); net loss $33.6M; provides 2023 guidance $63-68M ex-PAXLOVID

CODEXIS, INC.

2022-FY EPS reported -$0.51 revenue$138,590,000

FY2022 total revenue $138.6M (+32% YoY); ex-PAXLOVID revenue $63.2M (-10% YoY). Net loss $33.6M ($0.51/share) vs $21.3M loss in 2021.
Q4 2022 revenue $30.4M (+24% YoY); net loss $12.6M ($0.19/share) vs $10.2M loss in Q4 2021.
2023 guidance: total revenue $63-68M, product revenue $35-40M (both ex-PAXLOVID); gross margin 68-73%. Cash runway through end 2024.
Roche exercised ROFN on newly engineered DNA ligase for NGS; interim Phase 1 data for CDX-7108 (EPI) with Nestlé showed improved lipid absorption.
Upcoming IND filings: Nestlé for PKU (CDX-6114) H2 2023; Nestlé for EPI (CDX-7108) by end 2023; Takeda for Fabry as soon as late 2023.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

CODEXIS, INC. reported financial results for the fourth quarter ended December 31, 2022.

Period: the fourth quarter ended December 31, 2022
Result: reported results

Exact text from the filing

On February 23, 2023, Codexis, Inc. (the “Company”) announced its financial results for the fourth quarter and year ended December 31, 2022.

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

CODEXIS, INC. reported the fiscal year ended December 31, 2022 results: revenue $138.6 million.

Period: the fiscal year ended December 31, 2022
Revenue: $138.6 million
Result: reported results

Exact text from the filing

Total revenues for fiscal year 2022 were $138.6 million, an increase of 32% from $104.8 million the prior year.

View on SEC.gov

Browse all earnings releases →

CODEXIS, INC. filing history →

Source: SEC EDGAR

accession 0001200375-23-000009

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.